Aspen Labs Mexico – Carlos Abelleyra Cordero, CEO Spanish LATAM
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Ranked as the ninth largest generic company in the world, South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. The Group currently has 50 business units , 26 manufacturing facilities at 18 sites on 6 continents and approximately 8200 employees. In Latin America Aspen supplies a range of quality affordable products through its affiliate companies in Mexico, Argentina, Brazil and Venezuela as well as across the rest of Latin America in countries such as Chile, Colombia, Ecuador and the Carricam territories. Aspen sees Latin America as one of its key strategic regions with significant growth potential within the Group, and continues to seek opportunities to establish a greater presence in other Latin American countries.
Contact Details
Aspen Labs, S.A. De C.V.
Av. Insurgentes Sur 1685
Col. Guadalupe Inn, Del. Alvaro Obregón
C.P. 01020 México D.F.
Tel: +52 (55) 9126 0860
Website: aspenlabs.com.mx
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
Indian companies are increasingly interested in tapping into the alluring Mexican and Latin American pharmaceutical markets. The general manager of the API and drug producer discusses the vision behind the…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
Recognized by the University of Pennsylvania as one of the top 30 think tanks in the world for health policy, FUNSALUD is committed to propose solutions to Mexico’s most important…
In July 2012 COFEPRIS (the Federal Commission for the Protection against Sanitary Risk) was recognized as a national regulatory authority of regional reference by the PAHO (Pan-American Health Organization), opening…
The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came…
Latin America continues to be in the spotlight at Grünenthal. The managing director for Mexico explains how the company is strengthening its product portfolio, working with stakeholders to create more…
The president of CETIFARMA, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discusses the tireless effort it has made to professionalize the compliance function in…
The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical…
The executive director of the board bringing together multinational and local drug manufacturers talks about the chamber’s goal to position the pharmaceutical industry as the most important manufacturing sector in Mexico,…
Exactly 10 years ago Mexico realized that its public healthcare provision was inadequate as it was based on a system of employment benefits. This left over 50 million Mexicans…
Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced…
See our Cookie Privacy Policy Here
